|
**Overview**: Gaucher Disease Quantitative Panel**Introduction**: The Gaucher Disease Quantitative Panel is a diagnostic tool designed to screen for Gaucher disease using whole blood samples. In India, Gaucher disease (GBA deficiency) is the most common lysosomal storage disorder (~1 in 40,000â€"60,000), with type 1 (non-neuronopathic) predominant, presenting with hepatosplenomegaly, anemia, bone pain, and thrombocytopenia. High morbidity from underdiagnosis in rural/low-SES children/adults with unexplained splenomegaly, limited enzyme/genetic testing, delayed enzyme replacement therapy (ERT) or substrate reduction leading to irreversible bone disease or liver complications. Per molecular pathology practices aligned with ICMR and Indian Society of Human Genetics guidelines, the test employs PCR for GBA gene mutations and beta-glucocerebrosidase activity over 1-2 days with high accuracy, valuable for confirming diagnosis in suspected cases. This diagnostic falls under genetic disorder screening and targets patients with splenomegaly, cytopenias, or bone crises, addressing accurate detection to guide ERT and family counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise identification and reducing storage disorder burden. Its whole blood-based approach ensures reliable enzyme/mutation analysis.**Other Names**: Gaucher Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: GBA testing standard; in India, used in rare disease clinics.**Purpose**: The test assesses 2 parameters including GBA gene mutation to guide Gaucher disease screening, confirm deficiency, inform therapy.**Test Parameters**: 1. GBA Gene Mutation, 2. Beta-Glucocerebrosidase Activity.**Pretest Condition**: No fasting required; patients should report splenomegaly or bone pain.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for analysis).**Medical History**: Patients should provide details on hepatosplenomegaly, anemia, bone crises.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated Gaucher including bone disease, benefits of early detection, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR and enzyme assay by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low enzyme activity can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Mutation/low activity confirms Gaucher, necessitating specialist input. Normal may require follow-up.**Specialist Consultation**: Geneticists or hematologists should be consulted for management.**Additional Supporting Tests**: Chitotriosidase, lyso-Gb1 for confirmation.**Test Limitations**: May miss rare variants; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Metabolic Studies India 2023. |
